Eli Lilly to launch up to four new weight‑loss drugs in next four years
Eli Lilly's chairman and CEO David A. Ricks announced the company will introduce up to four new products in the weight‑loss category over the next four years, building on the $36 billion sales generated last year by Mounjaro and Zepbound. The firm, valued at $1.05 trillion, aims to maintain its lead in the market.1
Ricks highlighted India's strong scientific talent and manufacturing capabilities, stating that Lilly is open to discussions with Indian biotechnology companies for potential partnerships.1